LGND revenues were $12.4 million, compared with $5.8 million of revenues in the fourth quarter of 2007. Total revenues in 2008 were $27.3 million, compared with total revenues of $12.9 million in 2007. In addition to revenues from royalty payments related to sales of AVINZA®, fourth quarter and full year 2008 revenues include $5.0 million related to the license of LGD-4665 to GlaxoSmithKline and $2.0 million of milestones related to the FDA approval of PROMACTA®.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.